Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus VANOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus VANOS.
ALA-SCALP vs VANOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
VANOS (fluocinonide 0.1% cream) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2 and reduction of prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a 5% solution to the scalp twice daily.
Apply a thin layer to affected areas once or twice daily. Not for use longer than 2 weeks; maximum 15 g per day.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
The terminal elimination half-life is approximately 7.5 hours (range 5-12 hours). This supports twice-daily or once-daily dosing for sustained local effect.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily renal excretion (glucuronidation and sulfation); minimal biliary elimination (<5%). Approximately 60-70% of the dose is excreted in urine as metabolites, with <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid